Aratana Therapeutics, Inc. (NASDAQ: PETX) was founded in 2010 and is headquartered in Leawood, Kansas, USA. It has 84 full-time employees. It is an animal medicine pharmaceutical company that focuses on dog and cat (pet) therapeutics in the United States and Belgium. Licensing, development and commercialization.
Aratana Therapeutics, Inc. (PETX):
Aratana Therapeutics is a pioneer in pet therapy, focusing on licensing, developing and commercializing innovative therapies for dog and cat diseases. Aratana means “new beginning” and it defines the company’s mission to develop safe and effective treatments for unmet or underserved medical conditions for pets. The goal of Aratana Therapeutics is to provide veterinarians and pet owners with new therapies that are driven by science and made specifically for pets.
Historically, advances in veterinary medicine lag behind scientific breakthroughs in human health, and there is a lack of resources that can be used to develop medical treatments for pets suffering from chronic diseases.
The innovation gap between human science and veterinary science is the main reason why Aratana Therapeutics was established in Kansas City Animal Health Corridor in 2010. The company’s vision is and remains to find the best human drug development opportunities and apply them to veterinarians, especially to promote pet therapy-a new type of animal health company.
Aratana Therapeutics’ product portfolio includes a variety of treatments and therapeutic candidates consisting of small molecule drugs and biological agents. Company distribution or sales :
- ENTYCE, to enhance the appetite of dogs;
- GALLIPRANT, used to control pain and inflammation associated with dog osteoarthritis;
- NOCITA, a postoperative analgesia for canine cranial cruciate ligament surgery.
Aratana Therapeutics authorized products include:
- Canine osteosarcoma vaccine (canine osteosarcoma vaccine), a live Listeria carrier, is used in the United States to treat dogs diagnosed with osteosarcoma.
- AT-003, bupivacaine liposome injectable suspension for postoperative pain in cats.
- AT-002, a specific capromorelin formula, used in cats and dogs.
- AT-018, an oral CRTH2 antagonist, is used to treat atopic dermatitis in dogs.
- AT-006, an antiviral epiclovir, is used to treat ophthalmic diseases caused by feline herpes virus.
- AT-017, a Listeria-based antigen delivery system for the treatment of canine lymphoma.
- AT-019, EP4 receptor antagonist treatment candidate, has the potential to treat pain, inflammation and other indications.
- AT-008, a drug candidate for the treatment of canine lymphoma (Europe).
- In addition, Aratana Therapeutics has developed other treatments for dogs and cats in Europe.
Aratana Therapeutics signed a cooperation agreement with Elanco Animal Health, Inc. to develop, manufacture and commercialize GRAPIPRANT products; and cooperate with Japan’s AskAt Inc. to develop and commercialize the compound AT-019.